RxDoctor Payments Data

Emery Aaron, PA

Physician Assistant · Ruston, LANPI 1942907852

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 115 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$337
  • Pfizer$238
  • Takeda Pharmaceuticals U.S.A., Inc.$218
  • Amgen$197
  • AstraZeneca$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$98
  • plus $875 from 19 others

What the payments were for

  • Food & beverage$2,087100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 80th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,251
Medicare patients
126
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$29,542
MounjaroTirzepatide13$13,236
MyrbetriqMirabegron13$9,028
EliquisApixaban15$8,586
FarxigaDapagliflozin Propanediol11$6,299
CefuroximeCefuroxime Axetil41$786
Omeprazole61$633
Memantine Hcl ErMemantine Hcl11$528
Albuterol Sulfate HfaAlbuterol Sulfate18$509
Levothyroxine Sodium103$472
Atorvastatin Calcium84$309
Ezetimibe17$297
Doxycycline Hyclate38$274
Escitalopram Oxalate29$211
Potassium Chloride26$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$337$29,54221 claims
Lilly USA, LLCMounjaro$44$13,23613 claims
Astellas Pharma US IncMyrbetriq$74$9,02813 claims
PfizerEliquis$238$8,58615 claims
AstraZenecaFarxiga$125$6,29911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →